VIDEO ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL
ZILOVERTAMAB: POTENTIALLY FIRST-IN-CLASS MONOCLONAL ANTIBODY TARGETING ROR1 • Safety and efficacy results for zilovertamab + ibrutinib in patients with MCL/CLL compare favorably to historical single- agent ibrutinib. • Encouraging efficacy results in patients with p53 mutated CLL, with PFS of 100% at 24 and 30 months • Agreement with U.S. FDA on Phase 3 global registrational study design for the treatment of patients with R/R MCL
ONCT ROR1 Expressed on Multiple: Solid and Liquid Tumors MCL 95% CLL 95% Uterus 96% Lymphoma 90% Prostate 90%
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.